Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.
Industry, Sector and Symbol
Industry Investment offices, not elsewhere classified
Sub-IndustryN/A
SectorFinance
Phone617-772-8500
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Tekla Life Sciences Investors (NYSE:HQL) Frequently Asked Questions
What is Tekla Life Sciences Investors' stock symbol?
Tekla Life Sciences Investors trades on the New York Stock Exchange (NYSE) under the ticker symbol "HQL."
How often does Tekla Life Sciences Investors pay dividends? What is the dividend yield for Tekla Life Sciences Investors?
Tekla Life Sciences Investors declared a quarterly dividend on Wednesday, May 22nd. Shareholders of record on Friday, May 31st will be paid a dividend of $0.37 per share on Friday, June 28th. This represents a $1.48 dividend on an annualized basis and a yield of 9.33%. The ex-dividend date is Thursday, May 30th. This is a boost from Tekla Life Sciences Investors's previous quarterly dividend of $0.33. View Tekla Life Sciences Investors' Dividend History.
Has Tekla Life Sciences Investors been receiving favorable news coverage?
Press coverage about HQL stock has trended somewhat negative this week, InfoTrie reports. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Tekla Life Sciences Investors earned a media sentiment score of -1.3 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Tekla Life Sciences Investors.
Who are some of Tekla Life Sciences Investors' key competitors?
Some companies that are related to Tekla Life Sciences Investors include Hercules Capital (HTGC), Royce Value Trust (RVT), Liberty All-Star Equity Fund (USA), Boulder Growth & Income Fund (BIF), Tortoise Energy Infrastructure (TYG), Apollo Investment (AINV), AllianceBernstein Global Hgh Incm Fd (AWF), PIMCO High Income Fund (PHK), General American Investors (GAM), Blackrock Muniyield Insured Fund (MYI), Solar Capital (SLRC), Invesco Van Kampen Munpl Oprtnty Tr (VMO), Goldman Sachs BDC (GSBD), Templeton Global Income Fund (GIM) and Tekla Healthcare Investors (HQH).
What other stocks do shareholders of Tekla Life Sciences Investors own?
Who are Tekla Life Sciences Investors' key executives?
Tekla Life Sciences Investors' management team includes the folowing people:
- Dr. Daniel R. Omstead M.S, Ph.D., Principal Exec. Officer, Pres and Trustee (Age 66)
- Ms. Laura F. Woodward, Principal Financial Officer, Chief Compliance Officer, Sec. and Treasurer (Age 51)
- Ms. Betty T. Chang, Assistant Treasurer (Age 47)
Who are Tekla Life Sciences Investors' major shareholders?
Tekla Life Sciences Investors' stock is owned by many different of retail and institutional investors. Top institutional investors include Needham Investment Management LLC (2.28%), Morgan Stanley (1.59%), Flagship Harbor Advisors LLC (1.21%), Wells Fargo & Company MN (1.04%), Cohen & Steers Inc. (0.89%) and Invesco Ltd. (0.60%). View Institutional Ownership Trends for Tekla Life Sciences Investors.
Which major investors are selling Tekla Life Sciences Investors stock?
HQL stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., Ladenburg Thalmann Financial Services Inc., Needham Investment Management LLC, Wells Fargo & Company MN, LPL Financial LLC, Morgan Stanley, Claraphi Advisory Network LLC and Commonwealth Equity Services LLC. View Insider Buying and Selling for Tekla Life Sciences Investors.
Which major investors are buying Tekla Life Sciences Investors stock?
HQL stock was acquired by a variety of institutional investors in the last quarter, including Atlantic Union Bankshares Corp, First Trust Advisors LP, NEXT Financial Group Inc, Mid Atlantic Financial Management Inc. ADV, Cohen & Steers Inc., Advisor Group Inc., Bank of America Corp DE and Bank of Montreal Can. View Insider Buying and Selling for Tekla Life Sciences Investors.
How do I buy shares of Tekla Life Sciences Investors?
Shares of HQL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Tekla Life Sciences Investors' stock price today?
One share of HQL stock can currently be purchased for approximately $15.86.
How big of a company is Tekla Life Sciences Investors?
What is Tekla Life Sciences Investors' official website?
How can I contact Tekla Life Sciences Investors?
Tekla Life Sciences Investors' mailing address is 2 LIBERTY SQUARE 9TH FLOOR, BOSTON MA, 02109. The company can be reached via phone at 617-772-8500 or via email at [email protected]
MarketBeat Community Rating for Tekla Life Sciences Investors (NYSE HQL)
MarketBeat's community ratings are surveys of what our community members think about Tekla Life Sciences Investors and other stocks. Vote "Outperform" if you believe HQL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HQL will underperform the S&P 500 over the long term. You may vote once every thirty days.
